Overcoming Site Challenges in Oncology Trials – An interview with Penny Chipman
In this interview Penny Chipman, Manager of the Clinical Research Program at the Gerald Bronfman Centre for Clinical Research in…
Importance of Strategic Advisors & Strong Leadership
In my last post we looked at the need for a visionary drug development plan. Today’s post will outline the…
Importance of having a visionary drug development plan
In my last post we looked at the first of three essential assets that your team should look to acquire…
First Essential Asset for Successful Oncology Drug Development
Developing oncology compounds is a constantly evolving process, and with the dramatic rise in costs, making every step count is…
Reverse Feasibility in Action – Transcript of interview with Dr. Quincy Chu
In this interview, Dr. Quincy Chu, Medical Oncologist at the Cross Cancer Institute in Edmonton Alberta, discusses the ways in…
Value of Canadian oncology centers for early phase trials – Transcript of interview with Dr. Stephen Welch
Given the increased focus on speed of activation for oncology studies, sponsors are under pressure to select top-performing investigative sites…
Tips on developing oncology biomarkers and companion diagnostics – Transcript of interview with Dr. John Reddington
The increased demand for targeted therapeutics has prompted oncology drug developers to uncover innovative solutions to new challenges. Fueled by…
How to get the most out of data warehousing and analytics – Transcript of interview with Steve Sweeney
With the volume of medical data doubling every 5 years, the challenge has now become how to derive actionable insights…
Quality, Speed & Performance – Keys to Canada’s Future – Interview with Karen Arts of the Ontario Institute for Cancer Research
Canada boasts several centers of excellence with a group of internationally renowned investigators that are at the forefront of oncology…
Value of Canadian Oncology Centers for Early Phase Trials – Interview with Dr. Stephen Welch
Given the increased focus on speed of activation for oncology studies, sponsors are under pressure to select top-performing investigative sites…